GBIM:OTCMKTS
GlobeImmune Inc
0,00010 USD
0,00%
(0,00) 1D
29. ruj, 15:48:52 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za GBIM...
Trž. kap.
580,00
Prosj. kol.
1,74 tis.
Količina
0,00
52-tjed. najviša
0,04 USD
52-tjed. najniža
0,00 USD
Dionice u optjecaju
5,75 mil.
Broj djelatnika
22
Trž. kap.
580,00
Prosj. kol.
1,74 tis.
Količina
0,00
52-tjed. najviša
0,04 USD
52-tjed. najniža
0,00 USD
Dionice u optjecaju
5,75 mil.
Broj djelatnika
22
Vijesti
Iz web-izvora i od partnera za vijesti
Naslovi.net
·
prije 2 dana
Wall Street: S&P 500 gotovo nepromijenjen nakon objava rezultata velikih banaka
PR Newswire
·
prije 30 minuta
BCRF Launches $100 Million Venture Program for Breast Cancer: NYSE Content Update
www.marketscreener.com
·
prije 40 minuta
Fabric.AI to Participate in Live YouTube “Ask Me Anything” Panel from Nasdaq MarketSite on the Future of AI Infrastructure
Profil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
GlobeImmune Inc – informacije
Glavni izvršni direktor-
Zaposlenici22
Osnovano1. sij 1995.
SjedišteLouisville, Colorado, Sjedinjene Američke Države
Sektor-
Web-lokacijaglobeimmune.com